Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world Study of Growth Hormone for Growth Disorders in Pediatric Chronic Kidney Disease
ChiCTR2500104568Phase 4Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Jun 2025
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label trial of somatropin and genotropin miniquick in chronic kidney disease (CKD) and Growth disorder (2 arms), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Change in height standard deviation score (ΔHtSDS) after 52 weeks of treatment. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
somatropingenotropin miniquick
03
Conditions
chronic kidney disease (CKD)Growth disorder
Beyond the preview
Go deeper on ChiCTR2500104568.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104568.